Sphera Funds Management LTD Stake in Celgene Corp (CELG) Lifted by $3.54 Million as Stock Declined

May 26, 2018 - By Dolores Ford

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.83 in 2017 Q4. Its down 0.34, from 1.17 in 2017Q3. It worsened, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Eastern National Bank & Trust owns 149,103 shares. New York-based Alpine Woods Cap Investors Limited Liability Co has invested 0.04% in Celgene Corporation (NASDAQ:CELG). Moreover, Lafleur Godfrey Limited Liability Com has 0.07% invested in Celgene Corporation (NASDAQ:CELG). First Financial Corp In holds 0.03% or 463 shares in its portfolio. Ing Groep Nv holds 153,415 shares. Cardinal Capital holds 0.06% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 1,950 shares. Mutual Of America Management Ltd Liability holds 99,621 shares or 0.16% of its portfolio. Pillar Pacific Capital Mngmt Ltd Limited Liability Company, a California-based fund reported 73,991 shares. Moreover, Putnam Investments Limited Liability Corporation has 0.08% invested in Celgene Corporation (NASDAQ:CELG) for 356,435 shares. First Bank reported 23,747 shares. New York-based D E Shaw And has invested 0.11% in Celgene Corporation (NASDAQ:CELG). Novare Management Limited Liability Company stated it has 0.92% in Celgene Corporation (NASDAQ:CELG). Altfest L J And invested in 0.44% or 10,978 shares. Seminole reported 148,941 shares. Martingale Asset Management Lp holds 0.05% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 34,600 shares.

Since February 8, 2018, it had 2 buys, and 3 insider sales for $3.48 million activity. The insider Alles Mark J bought 3,260 shares worth $299,594. The insider KAPLAN GILLA sold $1.77 million. $851,093 worth of Celgene Corporation (NASDAQ:CELG) was sold by LOUGHLIN JAMES J.

Sphera Funds Management Ltd increased its stake in Celgene Corp (CELG) by 12.36% based on its latest 2017Q4 regulatory filing with the SEC. Sphera Funds Management Ltd bought 34,000 shares as the company’s stock declined 19.30% with the market. The institutional investor held 309,000 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $32.25 million, up from 275,000 at the end of the previous reported quarter. Sphera Funds Management Ltd who had been investing in Celgene Corp for a number of months, seems to be bullish on the $57.11 billion market cap company. The stock decreased 1.14% or $0.91 during the last trading session, reaching $78.63. About 4.78M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since May 26, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Sphera Funds Management Ltd, which manages about $852.23M US Long portfolio, decreased its stake in Immunomedics Inc (NASDAQ:IMMU) by 220,000 shares to 230,000 shares, valued at $3.72 million in 2017Q4, according to the filing. It also reduced its holding in Biogen Inc (NASDAQ:BIIB) by 30,800 shares in the quarter, leaving it with 74,200 shares, and cut its stake in Orbotech Ltd (NASDAQ:ORBK).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “My 2 Cents On The Ozanimod Saga” on May 15, 2018, also Seekingalpha.com with their article: “Will ‘Public Shaming’ Sink Celgene?” published on May 21, 2018, Seekingalpha.com published: “Goldman bearish on Celgene” on May 25, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Benzinga.com and their article: “Celgene Forges Oncology Partnership With Germany’s Evotec” published on May 22, 2018 as well as Finance.Yahoo.com‘s news article titled: “5 Top Stock Trades for Tuesday Morning” with publication date: May 22, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 22 analysts covering Celgene (NASDAQ:CELG), 15 have Buy rating, 0 Sell and 7 Hold. Therefore 68% are positive. Celgene had 38 analyst reports since December 8, 2017 according to SRatingsIntel. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by SunTrust on Monday, January 8. Piper Jaffray maintained Celgene Corporation (NASDAQ:CELG) on Thursday, January 25 with “Hold” rating. The stock has “Hold” rating by Piper Jaffray on Thursday, December 21. The company was maintained on Tuesday, January 23 by RBC Capital Markets. The rating was downgraded by Bank of America on Friday, January 5 to “Hold”. The rating was downgraded by SunTrust to “Hold” on Wednesday, February 28. SunTrust maintained Celgene Corporation (NASDAQ:CELG) on Friday, December 22 with “Buy” rating. The firm earned “Hold” rating on Thursday, January 18 by Piper Jaffray. Robert W. Baird maintained the stock with “Hold” rating in Wednesday, February 28 report. The rating was upgraded by Bernstein to “Buy” on Wednesday, May 23.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: